FMP
Belite Bio, Inc
BLTE
NASDAQ
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
56.21 USD
3.17 (5.64%)
GlobeNewsWire
Aug 5, 2024
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the second quarter ended June 30, 2024.
Seeking Alpha
May 14, 2024
Belite Bio, Inc. (NASDAQ:BLTE ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Basma Radwan - Leerink Partners Operator Hello, and thank you for joining us to discuss Belite Bio's First Quarter 2024 Financial Results.
Zacks Investment Research
Apr 10, 2024
The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Seeking Alpha
Mar 12, 2024
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
GlobeNewsWire
Mar 6, 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.
GlobeNewsWire
Feb 7, 2024
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place ...
Seeking Alpha
Nov 14, 2023
Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Kento Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Bruce Jackson - The Benchmark Company Operator Hello and thank you for joining us to discuss Belite's Third Quarter 2023 Financial Results. Joining the...
GlobeNewsWire
Nov 7, 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company's financial results for the third quarter ended September 30, 2023, and provide a general business update.
Zacks Investment Research
Aug 21, 2023
Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.
Seeking Alpha
Aug 13, 2023
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Fitzgerald & Co. Yi Chen - HC Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference...